免疫效应细胞相关血液毒性:EHA/EBMT共识分级与最佳实践建议
欧洲血液与骨髓移植学会(EBMT)与欧洲血液学协会(EHA)组织36名CAR T细胞专家通过系列虚拟会议及法国里尔为期2天的会议形成共识,针对CAR T细胞治疗后免疫效应细胞相关血液毒性(ICAHT)提出基于中性粒细胞减少深度和持续时间的分级系统(分早期0-30天与晚期+30天后),并提供危险因素、预输注评分系统(如CAR-HEMATOTOX评分)、诊断检查及管理(生长因子支持、抗感染预防、输血、自体造血干细胞支持、异基因造血细胞移植)的专家建议。
要点
- ICAHT是CAR T细胞治疗后最常见的不良事件,血细胞减少可深且持久并易致严重感染。
- 共识提出基于中性粒细胞减少深度和持续时间的ICAHT分级系统,分早期(0-30天)和晚期(+30天后)。
- 提供危险因素、预输注评分系统(如CAR-HEMATOTOX评分)及诊断检查建议,并给出管理共识推荐。
核心结论
- 作者提出将ICAHT作为免疫效应细胞治疗后的新型毒性类别,为其分级提供框架,综述危险因素文献,并概述诊断检查及短期和长期管理的专家建议。
研究设计与样本
- EBMT与EHA联合组织36名CAR T细胞专家参与系列虚拟会议,并在法国里尔举行为期2天的会议,基于讨论制定最佳实践建议。
主要发现
- 血细胞减少是CAR T细胞治疗后最常见的不良事件,可深且持久,并易致严重感染并发症。
- 近期全球调查显示当前实践模式仍存在相当大的异质性。
- 共识针对早期(0-30天)和晚期(+30天后)血细胞减少,建立了基于中性粒细胞减少深度和持续时间的分级系统。
- 提供了关于危险因素、可用预输注评分系统(如CAR-HEMATOTOX评分)和诊断检查的详细建议。
- 另设章节聚焦于在严重血液毒性背景下识别噬血现象。
关键数值与推荐
- ICAHT分级系统基于中性粒细胞减少的深度和持续时间,分为早期(第0-30天)和晚期(第+30天后)血细胞减少。
- 推荐使用预输注评分系统(如CAR-HEMATOTOX评分)进行风险评估。
- 管理共识推荐包括生长因子支持、抗感染预防、输血、自体造血干细胞支持以及异基因造血细胞移植。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hematological toxicity is the most common adverse event after chimeric antigen receptor (CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for severe infectious complications. In a recent worldwide survey, we demonstrated that there remains considerable heterogeneity in regard to current practice patterns. Here, we sought to build consensus on the grading and management of immune effector cell-associated hematotoxicity (ICAHT) after CAR T-cell therapy. For this purpose, a joint effort between the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA) involved an international panel of 36 CAR T-cell experts who met in a series of virtual conferences, culminating in a 2-day meeting in Lille, France. On the basis of these deliberations, best practice recommendations were developed. For the grading of ICAHT, a classification system based on depth and duration of neutropenia was developed for early (day 0-30) and late (after day +30) cytopenia. Detailed recommendations on risk factors, available preinfusion scoring systems (eg, CAR-HEMATOTOX score), and diagnostic workup are provided. A further section focuses on identifying hemophagocytosis in the context of severe hematotoxicity. Finally, we review current evidence and provide consensus recommendations for the management of ICAHT, including growth factor support, anti-infectious prophylaxis, transfusions, autologous hematopoietic stem cell boost, and allogeneic hematopoietic cell transplantation. In conclusion, we propose ICAHT as a novel toxicity category after immune effector cell therapy, provide a framework for its grading, review literature on risk factors, and outline expert recommendations for the diagnostic workup and short- and long-term management.
引用
- Rejeski K, Subklewe M, Aljurf M, et al. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 2023. PMID: 37300386. doi:10.1182/blood.2023020578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。